This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: M35.6 | Special Copayment Reduction: V139 (rare disease Special Copayment Reduction) |
| B. Synonyms | Relapsing panniculitis [Weber-Christian], Weber-Christian disease, Weber-Christian panniculitis, Nodular nonsuppurative panniculitis |
| C. Adult onset | Likelihood of first onset in adulthood: high — onset mainly in adults in their 30s to 60s, particularly obese middle-aged women. Pediatric onset has also been reported but is rare. |
| 1. History | First described by Pfeifer in 1892. Reported in detail by Weber in 1925 and Christian in 1928, respectively, and named 'Weber-Christian disease'. Later reclassified as part of the broad spectrum of relapsing panniculitis. |
| 2. Causes | Nonspecific inflammation of adipose tissue of unknown cause. Diverse causes, including forms associated with α1-antitrypsin deficiency, associated with pancreatic disease, drug-induced, tuberculous/infectious, and associated with connective tissue disease (lupus, dermatomyositis). |
| 3. Genetics | Genetic basis unknown. α1-Antitrypsin deficiency (PiZZ genotype) may be associated. No familial occurrence. HLA association not established. |
| 4. General epidemiology | Rare disease. On the order of several hundred cases worldwide. Female predominance (80%). Peak incidence in the 30s to 60s. Pediatric onset possible. Relatively common in obese women. |
| 5. Pathophysiology | Immune-mediated injury to adipocytes: infiltration of adipose tissue by neutrophils, macrophages, and T cells → adipocyte necrosis → granulomatous reaction → scarring fibrosis. There is also a form of fat necrosis caused by hypersecretion of pancreatic enzymes (lipase). |
| 6. Symptoms | Recurrent soft tissue masses, redness, and pain of the lower extremities (especially the pretibial area and thighs). The masses are tender subcutaneous nodules 1–5 cm in size. Spontaneous resolution followed by recurrence. Skin depression (lipoatrophy), oily discharge. Fever, fatigue, and arthralgia may accompany. |
| 7. Signs | Tender subcutaneous nodules (single to multiple) on the anterior lower extremities. In some, redness and warmth of the skin over the nodules. Depressed scars after spontaneous resolution. Tissue examination (mass biopsy) shows panniculitis and adipocyte necrosis. ESR·CRP elevated. |
| 8. Screening | No specific screening. The combination of recurrent tender subcutaneous nodules + fever is a screening indicator. Measurement of α1-antitrypsin level. Measurement of pancreatic enzymes (lipase, amylase), serum autoantibodies, serum ANA·dsDNA. |
| 9. Diagnosis | Tissue biopsy is essential. Pattern of panniculitis (lobular·septal), identification of the cause (α1-antitrypsin deficiency, association with pancreatic disease, connective tissue disease, etc.). Differentiation from erythema nodosum, subcutaneous lipoma, subcutaneous infection, etc. |
| 10. Treatment | Treatment of the cause takes priority. Nonspecific: NSAIDs, antimalarials (hydroxychloroquine), steroids. In severe cases, cyclosporine, MTX. In α1-antitrypsin deficiency, α1-antitrypsin replacement therapy. |
| 11. Prognosis | Alternating relapses and remissions. Most can remit spontaneously but relapse over several years. Can be fatal when accompanied by visceral panniculitis. Atrophic skin scars remain. |
| 12. Prevention | Primary prevention not possible. Smoking cessation in patients with α1-antitrypsin deficiency. Avoidance of relapse triggers. Early identification of the cause and treatment. |
| 13. References | White JW Jr., Winkelmann RK. Weber-Christian panniculitis … and 9 other references |
The clinical description of relapsing panniculitis dates back to the late 19th century. In 1892, the German physician Pfeifer first described a patient with recurrent subcutaneous nodules, but detailed clinical reports were made in the early 20th century. In 1925, the British physician Frederick Parkes Weber described the clinical features of this disease in detail, and in 1928, Henry Asbury Christian of the United States reported additional cases, establishing the name 'Weber-Christian disease' after the two men.
Weber-Christian disease was initially accepted as an independent disease entity, but in the late 20th century, criticism grew that the name was in fact merely a collective term for a common clinical phenotype of panniculitis due to various different causes. Panniculitis is a general term for inflammatory reactions occurring in adipose tissue (subcutaneous fat), and according to cause and histopathology it is classified into various subtypes, such as the erythema nodosum type, cold panniculitis, pancreatic panniculitis, α1-antitrypsin deficiency-associated panniculitis, connective tissue disease-associated panniculitis, traumatic panniculitis, and infectious panniculitis.
From the 1980s onward, α1-antitrypsin deficiency was recognized as one of the important causes of relapsing panniculitis, and α1-antitrypsin replacement therapy was reported to be effective in treating this form. From the 2000s onward, understanding deepened of panniculitis associated with connective tissue disease (lupus dermatitis, dermatomyositis), drug-induced panniculitis, panniculitis associated with leukocytoclastic vasculitis, and so on. Currently, the names 'Weber-Christian disease' or 'relapsing panniculitis' are either used restrictively for relapsing nodular panniculitis of unknown cause, or remain, in a historical context, as terms referring to the entire spectrum of panniculitis.
In Korea, there are several dozen case reports of relapsing panniculitis in the journals of the Korean Dermatological Association and the rheumatology society, and patients registered for Special Copayment Reduction (V139) are few. In East Asia, where the prevalence of α1-antitrypsin deficiency is lower than in Western countries, the form due to this cause is rare, and forms associated with connective tissue disease are presumed to be relatively more common.
Relapsing panniculitis is a clinical syndrome in which an inflammatory reaction occurs in adipose tissue through multiple mechanisms rather than a single cause. Classification by cause is important in clinical practice.
α1-Antitrypsin deficiency: α1-antitrypsin (AAT) is a neutrophil elastase inhibitor synthesized in the liver, and its deficiency increases tissue damage by neutrophil elastase. AAT deficiency is severe in the PiZZ genotype (bilateral Z alleles), and relapsing panniculitis frequently develops. AAT deficiency-associated panniculitis is relatively common in Western countries but rare in Asia.
Associated with pancreatic disease: a form in which excess lipase and amylase secreted in acute or chronic pancreatitis or pancreatic cancer reach the subcutaneous adipose tissue via the bloodstream and cause fat necrosis. Fat necrosis may also occur simultaneously within the abdominal cavity or around bones and joints. Measurement of serum lipase·amylase is important.
Associated with connective tissue disease: panniculitis may accompany connective tissue diseases such as systemic lupus erythematosus (lupus panniculitis = lupus profundus), dermatomyositis, scleroderma, and Sjögren syndrome. Identifying the underlying disease from the related autoantibodies and clinical findings is important for treatment.
Drug-induced: steroids (especially after abrupt discontinuation), iodides, bromides, insulin injection sites, anticancer agents (cyclophosphamide), etc. can induce panniculitis. Checking the medication history is essential.
Associated with infection: infections with Mycobacterium tuberculosis, nontuberculous mycobacteria, fungi, parasites, etc. can induce panniculitis. Infectious panniculitis is usually unilateral and localized and presents with signs of sepsis.
Idiopathic (unknown cause): cases in which no cause can be found even after all known causes have been excluded; the former 'Weber-Christian disease' corresponds to this category. There is currently debate as to whether patients in this category have a separate, independent disease or have a cause that has not yet been identified.
The genetic basis of relapsing panniculitis in general is unknown. However, genetic associations are known for certain causal forms. The clearest is α1-antitrypsin deficiency, in which homozygosity for the Z allele (Glu342Lys variant) of the SERPINA1 gene causes severe AAT deficiency, which is a risk factor for relapsing panniculitis. In carriers of the PiZZ genotype, AAT levels fall to 15% or less of normal, and the capacity of connective tissues, including adipose tissue, to defend against damage by neutrophil elastase is greatly reduced.
Lupus panniculitis shares the genetic predisposition of systemic lupus erythematosus (SLE), and associations with autoimmunity-related HLA alleles such as HLA-DR2 and HLA-DR3 have been confirmed across SLE. Dermatomyositis-associated panniculitis may also be associated with dermatomyositis risk genotypes such as HLA-DRB1*0301 and HLA-DQA1*0501. Otherwise, no specific gene associations have been established for idiopathic relapsing panniculitis.
Regarding the use of genetic testing in clinical practice, SERPINA1 genotype analysis (including phenotype) is essential when α1-antitrypsin deficiency is suspected. When there is a family history, evaluation for AAT deficiency is recommended.
Relapsing panniculitis (especially the idiopathic Weber-Christian form) is a very rare disease, with only several hundred case reports in the worldwide literature. Precise incidence and prevalence have not been established. About 80% of all cases occur in women, and the age of onset is mostly in the 30s to 60s. There are clinical observations that it is relatively more frequent in obese women, but there are no large-scale epidemiological studies.
Looking at the epidemiological distribution of panniculitis as a whole (including all subtypes), erythema nodosum is the most common form (annual incidence about 1–5/100,000), and all other forms combined are far less common than erythema nodosum. α1-Antitrypsin deficiency-associated panniculitis is relatively more common in Western countries, especially Scandinavia and Northern Europe, and rare in Asia because of the low frequency of the SERPINA1 Z allele. There are no precise epidemiological data for Korea, but based on the number of patients registered for Special Copayment Reduction, it is estimated to be at the level of a small number.
The pathophysiology of relapsing panniculitis differs by cause, but common to all is the core feature of an immune-mediated inflammatory reaction against subcutaneous adipose tissue (the fat layer, panniculus adiposus) and adipocyte necrosis.
Immune cell infiltration and adipocyte necrosis: in the early stage, neutrophils, followed by macrophages and lymphocytes, infiltrate the adipose tissue. In lobular panniculitis, inflammation occurs directly within the fat lobules, and in septal panniculitis, the septa between fat lobules (the connective tissue septa between fat lobules) are the main site of inflammation. Adipocyte necrosis causes lipid droplets to leak out, forming 'ghost cells' and fat necrosis.
Granulomatous reaction: subsequently, macrophages phagocytose the lipid droplets to form 'foamy macrophages', and in the chronic stage giant cell granulomas form. Finally, fibroblasts infiltrate and fibrosis occurs, leaving skin depression (lipoatrophy) and scarring.
Mechanism of α1-antitrypsin deficiency: in AAT deficiency, elastase, proteinase 3 (PR3), cathepsin G, etc. secreted by neutrophils are not inhibited in the tissue and directly destroy the adipose tissue. As a result, the subcutaneous nodules are not firm, and 'liquefactive necrosis' occurs, with the characteristic finding of nodules rupturing and discharging an oily brown fluid.
Fat necrosis due to pancreatic enzymes: lipase excessively secreted from the pancreas reaches the subcutaneous adipose tissue via the bloodstream and causes chemical fat necrosis by breaking down triglycerides into fatty acids and glycerol. The released fatty acids combine with calcium, causing saponification, and white, chalk-like deposits form in the tissue.
The main symptom of relapsing panniculitis is the recurrent development of subcutaneous nodules. The distribution of symptoms and accompanying findings differ somewhat by cause, but the typical symptoms of the idiopathic form are as follows.
Subcutaneous nodules: tender red subcutaneous nodules 1–5 cm in size develop on the lower extremities, especially the pretibial area and thighs. The nodules appear singly or in multiples, have reasonably well-defined borders, and are usually slightly adherent to the skin. The skin over the nodules is red or purplish and warm. The nodules resolve spontaneously within several weeks, but a relapsing pattern in which new ones then develop at the same or other sites is characteristic.
Skin depression (fat atrophy): after the nodules heal, skin depression (lipoatrophy, fat atrophy) due to loss of the fat layer may remain. In the α1-antitrypsin deficiency-associated form in particular, there is the characteristic finding of nodules rupturing and discharging an oily brown fluid (fat necrosis material).
Systemic symptoms: fever (38–40℃), fatigue, general malaise, weight loss, arthralgia, and myalgia may accompany. When systemic symptoms are severe, differentiation from connective tissue disease, hematologic malignancy, and infection is needed.
Visceral panniculitis: rarely, when the same panniculitis develops in peritoneal fat, mesenteric fat, or perivisceral fat, abdominal pain, ascites, fever, nausea, etc. may occur. Visceral panniculitis is rare but can be a life-threatening complication.
Joint symptoms: some patients have accompanying arthralgia or arthritis, with the ankle and knee joints being commonly involved.
The most characteristic finding on physical examination is tender subcutaneous nodules of the lower extremities. The nodules are usually 1–5 cm in diameter, firm or slightly soft to the touch, and adherent to the skin. The skin over the nodules shows redness and warmth, and older nodules show brown or purplish color changes.
Features of the α1-antitrypsin deficiency form: when the nodules soften and rupture, an oily yellowish-brown or brown fluid discharges. This fluid is liquefied fat necrosis material. Marked skin depression remaining after healing is characteristic.
Laboratory findings: ESR·CRP are elevated, and the complete blood count may show leukocytosis (during febrile periods) and anemia. Liver function test abnormalities are reported in some patients. When the serum α1-antitrypsin level is low, deficiency is suspected (normal 80–200 mg/dL). In the pancreatic form, serum lipase·amylase are elevated. In connective tissue disease-associated forms, ANA, anti-dsDNA antibodies, anti-Ro/La antibodies, etc. may be positive.
Histological findings: a sufficiently deep biopsy including the fat layer (subcutaneous fat) is essential. Lobular panniculitis: neutrophil and macrophage infiltration within fat lobules, adipocyte necrosis, 'ghost cells', foamy macrophages. Septal panniculitis: inflammatory cell infiltration and fibrosis of the septa between fat lobules. In the chronic phase, granulomas and fibrosis are prominent. The presence or absence of vascular involvement (vasculitis) is also checked.
There is no general screening test for relapsing panniculitis. In patients with recurrent tender subcutaneous nodules, systematic identification of the cause is key to diagnosis and treatment.
Basic blood tests: the basic evaluation consists of CBC, ESR, CRP, liver function tests, renal function tests, serum α1-antitrypsin (quantitative and electrophoretic phenotype), serum lipase·amylase (to exclude pancreatic disease), ANA, anti-dsDNA, anti-Ro/La, RF, anti-CCP, ANCA, serum protein electrophoresis, and quantitative immunoglobulins.
Skin biopsy: for confirmation, a biopsy that includes sufficient subcutaneous fat is performed on an active nodule. An incisional biopsy is more advantageous than a punch biopsy (4–6 mm) for obtaining sufficient tissue. In addition to H&E staining, the biopsy specimen is evaluated with PAS, AFB (acid-fast bacilli), bacterial culture, and immunohistochemical staining (IgG4, CD3, CD20, CD68, etc.).
Imaging: abdominal CT is useful for excluding visceral panniculitis, pancreatic disease, and retroperitoneal masses. If needed, MRI evaluates soft tissue lesions in greater detail.
SERPINA1 genotype analysis: when the serum α1-antitrypsin level is low or there is rupture of recurrent subcutaneous nodules with oily discharge, SERPINA1 genotype (PI*ZZ, PI*SZ, etc.) analysis is performed to confirm α1-antitrypsin deficiency.
The diagnosis of relapsing panniculitis is made by integrating clinical, laboratory, and histological findings, and identification of the cause is particularly the most important part of the diagnosis. There are currently no standardized international classification criteria.
Clinical diagnostic approach: in patients with recurrent tender subcutaneous nodules, fever, and elevated ESR, the following tests to identify the cause are performed sequentially: ① connective tissue disease-related autoantibodies (ANA, anti-dsDNA, anti-Sm, anti-Ro/La, RF, anti-CCP), ② serum α1-antitrypsin and SERPINA1 genotype, ③ serum lipase·amylase (pancreas-related), ④ infectious causes (Mycobacterium tuberculosis PCR and culture, fungal tests), ⑤ hematologic malignancy screening (serum LDH, protein electrophoresis, decision on bone marrow examination).
Interpretation of tissue biopsy: distinguishing lobular panniculitis vs septal panniculitis is useful for differential diagnosis. In lobular panniculitis, α1-antitrypsin deficiency-associated panniculitis, lupus panniculitis, and subcutaneous T-cell lymphoma are considered first. In septal panniculitis, erythema nodosum, nodular erythema multiforme, and superficial thrombophlebitis are differentiated first. If there are findings of vasculitis, panniculitis associated with leukocytoclastic vasculitis is considered.
Differential diagnosis: exclude erythema nodosum (septal lobular-border panniculitis, no depression after healing), cold panniculitis (history of cold exposure), subcutaneous T-cell lymphoma (atypical T-cell clone in tissue), subcutaneous lipoma (painless, no redness), deep infection (abscess, cellulitis), tuberculous skin lesions (lupus-like nodules), lipedema, etc.
In the treatment of relapsing panniculitis, specific treatment according to the cause is the top priority, and in addition to treating the cause, nonspecific treatment for symptom relief is given concurrently.
α1-Antitrypsin deficiency-associated form: intravenous infusion of purified α1-antitrypsin concentrate (60 mg/kg/week, individualized based on half-life) is the specific treatment. When treatment normalizes the serum AAT level, the capacity to inhibit neutrophil elastase is restored and the panniculitis improves. Smoking cessation is essential (smoking reduces AAT function).
NSAIDs and antimalarials: in nonspecific forms, NSAIDs such as ibuprofen help relieve pain and inflammation. Hydroxychloroquine (200–400 mg/day) has been reported to be effective in lupus panniculitis and the idiopathic form.
Corticosteroids: systemic steroids (prednisolone 0.5–1 mg/kg/day) are used in patients with severe relapses, visceral involvement, or systemic symptoms. However, relapse during steroid tapering is common.
Other immunosuppressants: methotrexate, cyclosporine A, azathioprine, and mycophenolate mofetil are used in steroid-refractory or steroid-dependent patients. In the systemic lupus erythematosus-associated form, standard treatment of the underlying disease (NSAIDs, antimalarials, steroids, immunosuppressants) also helps the panniculitis.
Removal of the cause: in the drug-induced form, discontinuation of the causative drug takes priority. In the pancreatic disease-associated form, treatment of the pancreatic disease (management of acute pancreatitis, correction of the cause of chronic pancreatitis) is most important for treating the panniculitis.
The prognosis of relapsing panniculitis varies with the cause and extent of involvement. The idiopathic form alternates between relapse and remission, but most can remit spontaneously, and a fatal course is rare. However, when there is visceral involvement, it can be life-threatening.
Prognosis of the idiopathic form: relapses and remissions alternating over several years are typical. Some patients reach spontaneous remission after several years. The main morbidity is skin depression (fat atrophy) and pigmentation remaining after healing. When accompanied by visceral panniculitis, fatal complications may occur.
α1-Antitrypsin deficiency-associated form: if untreated, relapses are frequent and skin depressions accumulate. Improvement is possible with AAT replacement therapy, but management of other AAT deficiency complications such as emphysema is also needed at the same time.
Connective tissue disease-associated form: waxes and wanes along with the activity of the underlying connective tissue disease. Lupus panniculitis can be controlled with SLE treatment (antimalarials, steroids), and marked depressions remain after healing. The dermatomyositis-associated form follows the prognosis associated with muscle and visceral involvement.
Primary prevention of relapsing panniculitis is impossible for most forms. However, in the α1-antitrypsin deficiency-associated form, smoking cessation is an effective primary prevention. Minimizing relapse through avoidance of triggering drugs and continued treatment of connective tissue disease is the key to prevention.
In patients with confirmed α1-antitrypsin deficiency, strict smoking cessation and avoidance of tobacco smoke are essential. Smoking further reduces AAT function, worsening both emphysema and panniculitis. Early detection of at-risk individuals through genotype testing of family members is also important. In patients with connective tissue disease, relapses of panniculitis are reduced by continuing treatment that minimizes disease activity. Abrupt discontinuation of steroids is avoided, and in the drug-induced form, the causative drug is avoided as much as possible.